Review of GLP-1RAs in Type 2 Diabetes and Atherosclerosis Mechanisms

Photo by National Cancer Institute / Unsplash

Frontiers in Medicine Published May 14, 2026 Medically reviewed May 14, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider that GLP-1RAs may modulate atherosclerotic pathways, but evidence remains preliminary and causal links are unproven.

This is a narrative review that synthesizes existing evidence on glucagon-like peptide-1 receptor agonists (GLP-1RAs) for patients with Type 2 Diabetes and atherosclerosis. The scope focuses on mechanistic pathways, including endothelial dysfunction, inflammatory signaling, oxidative stress pathways, plaque biology, extracellular matrix remodeling, immune-cell modulation, and circulating inflammatory mediators.

The authors discuss potential effects on NLRP3 inflammasome activity, oxidized LDL, nitric oxide (NO) availability, NOX-derived oxidative stress, adhesion molecule expression, macrophage behavior, cholesterol efflux, and metalloproteinase activity. No pooled effect sizes or quantitative syntheses are reported, as this is a qualitative review.

Key limitations noted include the lack of reported primary outcomes, sample sizes, follow-up durations, and safety data. The review does not describe specific study populations, interventions, comparators, or adverse events. The authors acknowledge that the evidence is preliminary and does not establish causality.

Practice relevance is not reported. Clinicians should interpret these mechanistic insights as hypothesis-generating rather than definitive guidance for treatment decisions.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Atherosclerosis is a chronic metabolic disorder driven by endothelial dysfunction, inflammation, oxidative stress, and progressive plaque remodeling; processes amplified in type 2 diabetes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for glycemic control, have emerged as modulators of vascular biology with potential anti-atherosclerotic effects. This review synthesizes evidence across key mechanistic domains, including endothelial dysfunction, inflammatory signaling, oxidative stress pathways, plaque biology, extracellular matrix remodeling, and immune-cell modulation. GLP-1RAs reduce circulating inflammatory mediators, suppress NLRP3 inflammasome activity, and lower oxidized LDL, thereby limiting the initiation of vascular injury. At the endothelial level, they enhance nitric oxide (NO) availability, decrease NOX-derived oxidative stress, and reduce adhesion molecule expression, collectively improving vascular function. Within plaques, GLP-1RA signaling alters macrophage behavior, promotes cholesterol efflux, and modulates metalloproteinase activity, suggesting potential effects on plaque composition and stability. Emerging biomarker platforms, including microRNA profiling and high-throughput proteomic and lipidomic signatures, together with advanced imaging approaches such as MRI-visible nano-GLP-1RA formulations, provide novel tools to monitor molecular and spatial drug effects in vivo. Collectively, these findings position GLP-1RAs as modulators of atherosclerotic disease beyond glycemic control, with integrated effects spanning systemic immunometabolism and plaque biology. By linking mechanistic insights with emerging imaging and multi-omics technologies, this review highlights a path toward biomarker-driven patient stratification and precision cardiovascular therapeutics, redefining how vascular risk is assessed and treated in metabolic disease.